Open AccessEfficacy and safety of сepeginterferon alfa-2b in the rteatment of chronic hepatitis c in outpatients.
Author(s) -
A. Mamonov,
Р. А. Мамонов
Publication year - 2018
Publication title -
kliničeskaâ medicina
Language(s) - English
Resource type - Journals
eISSN - 2412-1339
pISSN - 0023-2149
DOI - 10.18821/0023-2149-2017-95-11-1022-1025
Subject(s) - medicine , cirrhosis , chronic hepatitis , pegylated interferon , interferon alfa , interferon , hepatitis c virus , hepatitis c , gastroenterology , alpha interferon , virus , immunology , ribavirin
The features of the application of pegylated interferon - Сepeginterferon alfa2b (cepeg-IFN) on the results of treatment of 20 patients with chronic hepatitis C in outpatient practice. The analysis of the clinical, biochemical, virological data and transient liver elastometry on the background of antiviral therapy with cepeg-IFN. Based on these data is justified is not the worst in comparison with foreign analogues the efficacy and safety of the original domestic product for the treatment of patients with chronic hepatitis C, not previously treated with antiviral therapy, without a high degree of fibrosis or cirrhosis. Demonstrated clinical example of treatment failure associated with infection with a recombinant virus 2k1b and proposes an approach to the diagnosis of this variant infection